Skip Ribbon Commands
Skip to main content
Sign In
WHY WAIT TO GET SERIOUS ABOUT SEPARATION UNTIL THAT MOMENT WHEN YOU REALLY NEED IT?
See for yourself how to go from an apheresis product to separated cells in just one hour.
Elutra®
Cell Separation System*
Overview How It Works Specifications Materials
The Elutra system delivers:
  • CAPABILITY–Delivers cell enrichment or depletion all in a functionally closed system.
  • PURITY–Designed to provide high purity and recovery of cell populations without gradient solutions or expensive magnetic beads.
  • CONVENIENCE–Functionally closed, ready-to-use disposable tubing set minimizes setup time and reduces the risk of contamination.
  • CONTROL–Unique conical separation chamber allows consistent processing of cellular starting material in a single run.
  • VERSATILITY–Perform up to nine multistep separation profiles with a high degree of flexibility.
How It Works
How does counterflow elutriation work?

The Elutra system passes fluid through the cell layer established within a centrifugal field inside the separation chamber. By varying the flow of fluid in the opposite direction to the centrifugal force, the system aligns and collects particles according to size (smallest to largest) and density (lower to higher). Using both size and density as separation factors increases the resolution of cell separation compared to what is achieved with traditional centrifugation.

Watch the Elutra system in action

From existing dendritic cell (DC) maturation processes to newer chimeric antigen receptor (CAR) T-cell therapies, cell separation is playing a major role within these fast-growing fields of research and product development. Today, the Elutra system can be the answer when your process requires high recoveries and purities of monocytes and lymphocytes.

What Makes the Elutra System Different
High yields
Excellent purity
Consistent reliability
Compare the Elutra system to other cell separation methods.
ELUTRA SYSTEM

Cells remain untouched throughout the process

Functionally closed system reduces risk for contamination

Disposable sterile tubing set minimizes cross-contamination risk and makes for easy setup and use

No bead extraction necessary
OTHER CELL SEPARATION METHODS

Gradient solutions or antibody-coated beads are added to the apheresis product and often remain as part of the final cell product

Open system poses an inherent risk for contamination

Sterilization and cleaning between uses reduces lab productivity and heightens risk for contamination

Magnetic separation methods require a bead extraction step, which can significantly reduce final cell populations
Specifications

TUBING SET

Separation chamber volume: 40 mL
Number of collection bags: 6
Plastic: non-pyrogenic, biocompatible, sterilized with ethylene oxide

USER CONFIGURABLE PROFILES

Nine, including a sample monocyte enrichment protocol

MANUAL MODE

Pumps, centrifuge speed and ramp rates are fully controlled by the operator

EQUIPMENT

Centrifuge speed: 300 rpm to 2,600 rpm
Pump flow rates: 0 mL/min to 150 mL/min
Elutriation media volume: 500 mL to 12,000 mL
Fraction collection capability: 12

EQUIPMENT

Weight: 177 kg (389 lb)
Height: 180.3 cm (71 in)
Width: 70 cm (27.6 in)
Depth: 68 cm (26.7 in)

LINE VOLTAGE

100 ± 10% V AC, 50/60 Hz
115 ± 10% V AC, 50/60 Hz
230 ± 10% V AC, 50/60 Hz
240 ± 10% V AC, 50/60 Hz

INPUT LINE CURRENT

8 A maximum RMS at 100/115 V AC
4 A maximum RMS at 230/240 V AC

1Read EJ, et al., NIH Department of Transfusion Medicine, Bethesda, MD; Gambro BCT, Lakewood, CO. "Evaluation of a Closed Automated System to Isolate Peripheral Blood Monocytes for Dendritic Cell (DC) Immunotherapy." Ninth annual meeting of the ISCT, 29 May to 1 June 2003.

2Powell DJ, et al., "Efficient Clinical-Scale Enrichment of Lymphocytes for Use in Adoptive Immunotherapy Using a Modified Counterflow Centrifugal Elutriation Program." Cytotherapy 2009; 11 (7): 923–935.

Typical results based on cell counts from a leukapheresis product collected the previous day from normal donors on a COBE® Spectra Apheresis System. 80 mL to 230 mL products contained 5 to 14 × 109 WBC count, 80 percent to 100 percent mononuclear cell and 1.8 mL to 4.7 mL red blood cell volume.

*Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.

​​​​​​​​​​​